Clinical Competition Candidate
XALKORI
XALKORI carries substance and product and use-code patents, moderate complexity (2/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 40 months away. Active clinical competition may compress the generic entry window.
LOE window
40months
to latest listed patent expiry (November 6, 2029)
Expiry attractiveness: 4/5
Patent profile
Substance patent (listed)
Product / formulation patent (listed)
Use-code patent (listed)
Patent count: 5
Complexity score: 2/5
Clinical competition
Score: 5/5
Active trials linked: 195
Phase 2/3 trials: 106
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: CRIZOTINIB
Applicant (NDA holder): PF PRISM CV
Confidence: High